Learn more about the differences between our 2 internal medicine CME/MOC courses. Board Review offers you one big comprehensive pre-assessment to help you identify your knowledge gaps and create a personalized study plan.
We’ve been studying how physicians learn best and what their needs are for more than 7 years now, deeply researching these things, so I feel like we’ve made some headway in understanding how to best enable each learner a personally meaningful experience.
In recognition of Atrial Fibrillation Awareness month, we wanted to highlight a few of the AF-related studies presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain.
What you need is to combine the knowledge you've acquired with a solid test-taking strategy to be successful. Here are eight practical tips to help you put those two pieces together.
Are you prepared for the ECG and Imaging Studies component of the Cardiology Board Exam?
What you need is to combine the knowledge you've acquired with a solid test-taking strategy to be successful. Here are ten practical tips to help you put those two pieces together.
K2P products meet the needs and interests of our physician learners. And not just the need to master the basics of disease X or Y, but the desire to meet each patient where they are to provide true healing.
The American College of Cardiology/American Heart Association Task Force on Clinical Data Standards published a report June 23 listing and defining key data elements related to cardiovascular and noncardiovascular complications of COVID-19.
Instead of sitting for the traditional 10-year MOC exam, LKA participants choose when and where to answer assessment questions, find out in real-time if they were right or wrong, and receive a rationale and references to provide context and enhance learning.
The world of advanced heart failure is relatively small and specialized, but the most important thing learners should know is when to identify a patient who's heading down that slippery slope of advanced heart failure.
Dr. Bakris has been extensively involved as either a principal investigator or on the steering committees of national and international trials involving diabetic kidney disease progression and resistant hypertension. There are many people with different types of hypertension, isolated, systolic, masked, and white coat hypertension. Continue reading...
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.